Sichuan Kelun-Biotech Biopharmaceutical patents new heterocyclic compounds

June 18, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer.

BioWorld Science Cancer Antibody-drug conjugate Patents

Today's news in brief

BioWorld

BioWorld briefs for July 6, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Neuracle eyes Shanghai IPO as global BCI funding surges

BioWorld

Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...